These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32640027)

  • 1. Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer's Disease.
    Alvarez XA; Alvarez I; Martinez A; Romero I; Benito C; Suarez I; Mourente S; Fantini M; Figueroa J; Aleixandre M; Linares C; Muresanu D; Winter S; Moessler H
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):581-586. PubMed ID: 32640027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
    Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
    Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil.
    Chapman SB; Weiner MF; Rackley A; Hynan LS; Zientz J
    J Speech Lang Hear Res; 2004 Oct; 47(5):1149-63. PubMed ID: 15603468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
    Li DQ; Zhou YP; Yang H
    Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases.
    Alvarez XA; Alvarez I; Iglesias O; Crespo I; Figueroa J; Aleixandre M; Linares C; Granizo E; Garcia-Fantini M; Marey J; Masliah E; Winter S; Muresanu D; Moessler H
    Int J Neuropsychopharmacol; 2016 Jun; 19(6):. PubMed ID: 27207906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers.
    Alvarez XA; Alvarez I; Aleixandre M; Linares C; Muresanu D; Winter S; Moessler H
    J Alzheimers Dis; 2018; 63(3):1003-1013. PubMed ID: 29710700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
    Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
    Tariot P; Salloway S; Yardley J; Mackell J; Moline M
    BMC Res Notes; 2012 Jun; 5():283. PubMed ID: 22681723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial.
    Traini E; Carotenuto A; Fasanaro AM; Amenta F
    J Alzheimers Dis; 2020; 76(1):317-329. PubMed ID: 32508323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
    Homma A; Atarashi H; Kubota N; Nakai K; Takase T
    J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect and Safety of Huannao Yicong Formula () in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial.
    Yang Y; Liu JP; Fang JY; Wang HC; Wei Y; Cao Y; Liu JG; Liu LT; Li H
    Chin J Integr Med; 2019 Aug; 25(8):574-581. PubMed ID: 30109588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
    Wang J; Guo X; Lu W; Liu J; Zhang H; Quan Q; Su H; Ma L; Gao F; Qu Q
    J Alzheimers Dis; 2021; 80(2):673-681. PubMed ID: 33579850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.